CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th Annual Growth Conference, which takes place August 13-15, 2024, at the InterContinental Boston Hotel in Boston, MA. John Aballi, Exagen’s President and Chief Executive Officer will participate in a fireside chat on Wednesday, August 14th, at 2:30 PM ET. Interested parties may access the webcast of the presentation using a link on Exagen’s website at https://investors.exagen.com/events.
About Exagen Inc.
Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.
For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).
Contact:
Ryan Douglas
Exagen Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
760.560.1525
| Last Trade: | US$5.33 |
| Daily Change: | 0.31 6.18 |
| Daily Volume: | 421,724 |
| Market Cap: | US$94.020M |
January 12, 2025 November 14, 2024 November 12, 2024 October 21, 2024 August 05, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
